{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:22:08Z","timestamp":1789150928068,"version":"build-2803163510"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01708-w","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T11:51:12Z","timestamp":1749556272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Donepezil for cancer-related cognitive impairment: systematic review and meta-analysis"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0369-6981","authenticated-orcid":false,"given":"Micha\u0142","family":"Fornalik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5475-3216","authenticated-orcid":false,"given":"Sandra","family":"Moska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3576-7570","authenticated-orcid":false,"given":"Mariola","family":"Gim\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9648-7161","authenticated-orcid":false,"given":"Andriy","family":"Yabluchanskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2820-8703","authenticated-orcid":false,"given":"Camila","family":"Bonin Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"1708_CR1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3109\/09540261.2013.864260","volume":"26","author":"MC Janelsins","year":"2014","unstructured":"Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26:102\u201313. https:\/\/doi.org\/10.3109\/09540261.2013.864260.","journal-title":"Int Rev Psychiatry"},{"key":"1708_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s11764-015-0476-5","volume":"10","author":"JE Schmidt","year":"2016","unstructured":"Schmidt JE, Beckjord E, Bovbjerg DH, et al. Prevalence of perceived cognitive dysfunction in survivors of a wide range of cancers: results from the 2010 LIVESTRONG survey. J Cancer Surviv. 2016;10:302\u201311. https:\/\/doi.org\/10.1007\/s11764-015-0476-5.","journal-title":"J Cancer Surviv"},{"key":"1708_CR3","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/pon.5131","volume":"28","author":"NG Regier","year":"2019","unstructured":"Regier NG, Naik AD, Mulligan EA, et al. Cancer-related cognitive impairment and associated factors in a sample of older male oral-digestive cancer survivors. Psychooncology. 2019;28:1551\u20138. https:\/\/doi.org\/10.1002\/pon.5131.","journal-title":"Psychooncology"},{"key":"1708_CR4","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jgo.2020.02.008","volume":"11","author":"N Mir","year":"2020","unstructured":"Mir N, MacLennan P, Al-Obaidi M, et al. Patient-reported cognitive complaints in older adults with gastrointestinal malignancies at diagnosis\u2014results from the cancer & aging resilience evaluation (CARE) study. J Geriatr Oncol. 2020;11:982\u20138. https:\/\/doi.org\/10.1016\/j.jgo.2020.02.008.","journal-title":"J Geriatr Oncol"},{"key":"1708_CR5","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S1470-2045(10)70294-1","volume":"12","author":"JS Wefel","year":"2011","unstructured":"Wefel JS, Vardy J, Ahles T, Schagen SB. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12:703\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(10)70294-1.","journal-title":"Lancet Oncol"},{"key":"1708_CR6","doi-asserted-by":"publisher","first-page":"S498","DOI":"10.1016\/j.amepre.2015.08.013","volume":"49","author":"ND Buchanan","year":"2015","unstructured":"Buchanan ND, Dasari S, Rodriguez JL, et al. Post-treatment neurocognition and psychosocial care among breast cancer survivors. Am J Prev Med. 2015;49:S498\u2013508. https:\/\/doi.org\/10.1016\/j.amepre.2015.08.013.","journal-title":"Am J Prev Med"},{"key":"1708_CR7","first-page":"36","volume":"15","author":"JC Pendergrass","year":"2018","unstructured":"Pendergrass JC, Targum SD, Harrison JE. Cognitive impairment associated with cancer: a brief review. Innov Clin Neurosci. 2018;15:36\u201344 (PMID: 29497579).","journal-title":"Innov Clin Neurosci"},{"key":"1708_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/JTO.0000000000000345","volume":"10","author":"M Sim\u00f3","year":"2015","unstructured":"Sim\u00f3 M, Root JC, Vaquero L, et al. Cognitive and brain structural changes in a lung cancer population. J Thorac Oncol. 2015;10:38\u201345. https:\/\/doi.org\/10.1097\/JTO.0000000000000345.","journal-title":"J Thorac Oncol"},{"key":"1708_CR9","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1200\/JCO.2015.63.0905","volume":"33","author":"JL Vardy","year":"2015","unstructured":"Vardy JL, Dhillon HM, Pond GR, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 2015;33:4085\u201392. https:\/\/doi.org\/10.1200\/JCO.2015.63.0905.","journal-title":"J Clin Oncol"},{"key":"1708_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3390\/cancers11050687","volume":"11","author":"B Olson","year":"2019","unstructured":"Olson B, Marks DL. Pretreatment cancer-related cognitive impairment\u2014mechanisms and outlook. Cancers. 2019;11:687. https:\/\/doi.org\/10.3390\/cancers11050687.","journal-title":"Cancers"},{"key":"1708_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071726","author":"B Fleming","year":"2023","unstructured":"Fleming B, Edison P, Kenny L. Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management. BMJ. 2023. https:\/\/doi.org\/10.1136\/bmj-2022-071726.","journal-title":"BMJ"},{"key":"1708_CR12","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1080\/13548506.2018.1500023","volume":"23","author":"G Bolton","year":"2018","unstructured":"Bolton G, Isaacs A. Women\u2019s experiences of cancer-related cognitive impairment, its impact on daily life and care received for it following treatment for breast cancer. Psychol Health Med. 2018;23:1261\u201374. https:\/\/doi.org\/10.1080\/13548506.2018.1500023.","journal-title":"Psychol Health Med"},{"key":"1708_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108002","volume":"9","author":"MH Selamat","year":"2014","unstructured":"Selamat MH, Loh SY, Mackenzie L, Vardy J. Chemobrain experienced by breast cancer survivors: a meta-ethnography study investigating research and care implications. PLoS ONE. 2014;9: e108002. https:\/\/doi.org\/10.1371\/journal.pone.0108002.","journal-title":"PLoS ONE"},{"key":"1708_CR14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10549-012-2210-6","volume":"135","author":"D Von Ah","year":"2012","unstructured":"Von Ah D, Carpenter JS, Saykin A, et al. Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat. 2012;135:799\u2013809. https:\/\/doi.org\/10.1007\/s10549-012-2210-6.","journal-title":"Breast Cancer Res Treat"},{"key":"1708_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.clineuro.2012.05.024","volume":"115","author":"EC Miotto","year":"2013","unstructured":"Miotto EC, Savage CR, Evans JJ, et al. Semantic strategy training increases memory performance and brain activity in patients with prefrontal cortex lesions. Clin Neurol Neurosurg. 2013;115:309\u201316. https:\/\/doi.org\/10.1016\/j.clineuro.2012.05.024.","journal-title":"Clin Neurol Neurosurg"},{"key":"1708_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-023-01436-8","author":"M Duivon","year":"2023","unstructured":"Duivon M, Lange M, Binarelli G, et al. Improve the management of cancer-related cognitive impairment in clinical settings: a European Delphi study. J Cancer Surviv. 2023. https:\/\/doi.org\/10.1007\/s11764-023-01436-8.","journal-title":"J Cancer Surviv"},{"key":"1708_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1748-5908-5-75","volume":"5","author":"MR Kauth","year":"2010","unstructured":"Kauth MR, Sullivan G, Blevins D, et al. Employing external facilitation to implement cognitive behavioral therapy in VA clinics: a pilot study. Implement Sci. 2010;5:75. https:\/\/doi.org\/10.1186\/1748-5908-5-75.","journal-title":"Implement Sci"},{"key":"1708_CR18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41746-024-01210-9","volume":"7","author":"L Liu","year":"2024","unstructured":"Liu L, Wang H, Xing Y, et al. Dose\u2013response relationship between computerized cognitive training and cognitive improvement. npj Digit Med. 2024;7:214. https:\/\/doi.org\/10.1038\/s41746-024-01210-9.","journal-title":"npj Digit Med"},{"key":"1708_CR19","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2018.66","author":"R Wartena","year":"2018","unstructured":"Wartena R, Brandsma D, Belderbos J. Are memantine, methylphenidate and donepezil effective in sparing cognitive functioning after brain irradiation? J Cancer Metastasis Treat. 2018. https:\/\/doi.org\/10.20517\/2394-4722.2018.66.","journal-title":"J Cancer Metastasis Treat"},{"key":"1708_CR20","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.17219\/acem\/176051","volume":"33","author":"Y Gao","year":"2024","unstructured":"Gao Y, Liu Y, Li Y. Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer\u2019s disease: a systematic review and meta-analysis. Adv Clin Exp Med. 2024;33:1179. https:\/\/doi.org\/10.17219\/acem\/176051.","journal-title":"Adv Clin Exp Med"},{"key":"1708_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2125.2004.01848.x","volume":"58","author":"S Jackson","year":"2004","unstructured":"Jackson S, Ham RJ, Wilkinson D. The safety and tolerability of donepezil in patients with Alzheimer\u2019s disease. Br J Clin Pharmacol. 2004;58:1\u20138. https:\/\/doi.org\/10.1111\/j.1365-2125.2004.01848.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1708_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108352","volume":"190","author":"G Marucci","year":"2021","unstructured":"Marucci G, Buccioni M, Ben DD, et al. Efficacy of acetylcholinesterase inhibitors in Alzheimer\u2019s disease. Neuropharmacology. 2021;190: 108352. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108352.","journal-title":"Neuropharmacology"},{"key":"1708_CR23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1177\/026988110001400410","volume":"14","author":"NR Dunn","year":"2000","unstructured":"Dunn NR, Pearce GL, Shakir SAW. Adverse effects associated with the use of donepezil in general practice in England. J Psychopharmacol (Oxf). 2000;14:406\u20138. https:\/\/doi.org\/10.1177\/026988110001400410.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"1708_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1586\/14737175.1.1.61","volume":"1","author":"S Moghul","year":"2001","unstructured":"Moghul S, Wilkinson D. Use of acetylcholinesterase inhibitors in Alzheimer\u2019s disease. Expert Rev Neurother. 2001;1:61\u20139. https:\/\/doi.org\/10.1586\/14737175.1.1.61.","journal-title":"Expert Rev Neurother"},{"key":"1708_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1527-3458.2001.tb00204.x","volume":"7","author":"M Shigeta","year":"2001","unstructured":"Shigeta M, Homma A. Donepezil for Alzheimer\u2019s disease: pharmacodynamic, pharmacokinetic, and clinical profiles. CNS Drug Rev. 2001;7:353\u201368. https:\/\/doi.org\/10.1111\/j.1527-3458.2001.tb00204.x.","journal-title":"CNS Drug Rev"},{"key":"1708_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3233\/JAD-220530","volume":"90","author":"PN Tariot","year":"2022","unstructured":"Tariot PN, Braeckman R, Oh C. Comparison of steady-state pharmacokinetics of donepezil transdermal delivery system with oral donepezil. J Alzheimers Dis. 2022;90:161\u201372. https:\/\/doi.org\/10.3233\/JAD-220530.","journal-title":"J Alzheimers Dis"},{"key":"1708_CR27","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/09602011.2011.582708","volume":"21","author":"WH Chang","year":"2011","unstructured":"Chang WH, Park YH, Ohn SH, et al. Neural correlates of donepezil-induced cognitive improvement in patients with right hemisphere stroke: a pilot study. Neuropsychol Rehabil. 2011;21:502\u201314. https:\/\/doi.org\/10.1080\/09602011.2011.582708.","journal-title":"Neuropsychol Rehabil"},{"key":"1708_CR28","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.4103\/1673-5374.389628","volume":"19","author":"AL Miller","year":"2024","unstructured":"Miller AL, Evanson NK, Taylor JM. Use of donepezil for neurocognitive recovery after brain injury in adult and pediatric populations: a scoping review. Neural Regen Res. 2024;19:1685\u201395. https:\/\/doi.org\/10.4103\/1673-5374.389628.","journal-title":"Neural Regen Res"},{"key":"1708_CR29","doi-asserted-by":"publisher","DOI":"10.4137\/CMT.S5410","author":"V Jelic","year":"2010","unstructured":"Jelic V, Darreh-Shori T. Donepezil: a review of pharmacological characteristics and role in the management of Alzheimer disease. Clin Med Insights Ther. 2010. https:\/\/doi.org\/10.4137\/CMT.S5410.","journal-title":"Clin Med Insights Ther"},{"key":"1708_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1188\/14.CJON.S3.17-25","volume":"18","author":"D Von Ah","year":"2014","unstructured":"Von Ah D, Jansen CE, Allen DH. Evidence-based interventions for cancer- and treatment-related cognitive impairment. Clin J Oncol Nurs. 2014;18:17\u201325. https:\/\/doi.org\/10.1188\/14.CJON.S3.17-25.","journal-title":"Clin J Oncol Nurs"},{"key":"1708_CR31","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1016\/S1470-2045(18)30938-0","volume":"20","author":"P Karschnia","year":"2019","unstructured":"Karschnia P, Parsons MW, Dietrich J. Pharmacologic management of cognitive impairment induced by cancer therapy. Lancet Oncol. 2019;20:e92\u2013102. https:\/\/doi.org\/10.1016\/S1470-2045(18)30938-0.","journal-title":"Lancet Oncol"},{"key":"1708_CR32","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.neuropharm.2011.07.013","volume":"61","author":"G Winocur","year":"2011","unstructured":"Winocur G, Binns MA, Tannock I. Donepezil reduces cognitive impairment associated with anti-cancer drugs in a mouse model. Neuropharmacology. 2011;61:1222\u20138. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.07.013.","journal-title":"Neuropharmacology"},{"key":"1708_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6945415","author":"I Lim","year":"2016","unstructured":"Lim I, Joung HY, Yu AR, et al. PET evidence of the effect of donepezil on cognitive performance in an animal model of chemobrain. BioMed Res Int. 2016. https:\/\/doi.org\/10.1155\/2016\/6945415.","journal-title":"BioMed Res Int"},{"key":"1708_CR34","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s13311-023-01347-7","volume":"18","author":"B Ongnok","year":"2021","unstructured":"Ongnok B, Khuanjing T, Chunchai T, et al. Donepezil protects against doxorubicin-induced chemobrain in rats via attenuation of inflammation and oxidative stress without interfering with doxorubicin efficacy. Neurotherapeutics. 2021;18:2107\u201325. https:\/\/doi.org\/10.1007\/s13311-023-01347-7.","journal-title":"Neurotherapeutics"},{"key":"1708_CR35","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/s0885-3924(03)00332-4","volume":"26","author":"E Bruera","year":"2003","unstructured":"Bruera E, Strasser F, Shen L, et al. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manag. 2003;26:1049\u201354. https:\/\/doi.org\/10.1016\/s0885-3924(03)00332-4.","journal-title":"J Pain Symptom Manag"},{"key":"1708_CR36","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.2005.03.3001","volume":"24","author":"EG Shaw","year":"2006","unstructured":"Shaw EG, Rosdhal R, D\u2019Agostino RB Jr, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006;24:1415\u201320. https:\/\/doi.org\/10.1200\/JCO.2005.03.3001.","journal-title":"J Clin Oncol"},{"key":"1708_CR37","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/pbc.24078","volume":"59","author":"SM Castellino","year":"2012","unstructured":"Castellino SM, Tooze JA, Flowers L, et al. Toxicity and efficacy of the acetylcholinesterase (AChe) inhibitor donepezil in childhood brain tumor survivors: a pilot study. Pediatr Blood Cancer. 2012;59:540\u20137. https:\/\/doi.org\/10.1002\/pbc.24078.","journal-title":"Pediatr Blood Cancer"},{"key":"1708_CR38","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-015-2035-3","volume":"127","author":"DD Correa","year":"2016","unstructured":"Correa DD, Kryza-Lacombe M, Baser RE, et al. Cognitive effects of donepezil therapy in patients with brain tumors: a pilot study. J Neurooncol. 2016;127:313\u20139. https:\/\/doi.org\/10.1007\/s11060-015-2035-3.","journal-title":"J Neurooncol"},{"key":"1708_CR39","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1200\/JCO.2014.58.4508","volume":"33","author":"SR Rapp","year":"2015","unstructured":"Rapp SR, Case LD, Peiffer A, et al. Donepezil for irradiated brain tumor survivors: a phase III randomized placebo-controlled clinical trial. J Clin Oncol. 2015;33:1653\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.58.4508.","journal-title":"J Clin Oncol"},{"key":"1708_CR40","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/nop\/npx016","volume":"5","author":"MJ Naughton","year":"2018","unstructured":"Naughton MJ, Douglas Case L, Peiffer A, et al. Quality of life of irradiated brain tumor survivors treated with donepezil or placebo: results of the WFU CCOP research base protocol 91105. Neuro-Oncol Pract. 2018;5:114\u201321. https:\/\/doi.org\/10.1093\/nop\/npx016.","journal-title":"Neuro-Oncol Pract"},{"key":"1708_CR41","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s11764-015-0463-x","volume":"10","author":"JA Lawrence","year":"2016","unstructured":"Lawrence JA, Griffin L, Balcueva EP, et al. A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J Cancer Surviv Res Pract. 2016;10:176\u201384. https:\/\/doi.org\/10.1007\/s11764-015-0463-x.","journal-title":"J Cancer Surviv Res Pract"},{"key":"1708_CR42","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1200\/JCO.2007.10.9231","volume":"25","author":"E Bruera","year":"2007","unstructured":"Bruera E, El Osta B, Valero V, et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2007;25:3475\u201381. https:\/\/doi.org\/10.1200\/JCO.2007.10.9231.","journal-title":"J Clin Oncol"},{"key":"1708_CR43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01100","author":"SR Rapp","year":"2024","unstructured":"Rapp SR, Dressler EV, Brown WM, et al. Phase III randomized, placebo-controlled clinical trial of donepezil for treatment of cognitive impairment in breast cancer survivors after adjuvant chemotherapy (WF-97116). J Clin Oncol Off J Am Soc Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.23.01100.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1708_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1708_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.glmedi.2023.100046","volume":"2","author":"M-S Hosseini","year":"2024","unstructured":"Hosseini M-S, Jahanshahlou F, Akbarzadeh MA, et al. Formulating research questions for evidence-based studies. J Med Surg Public Health. 2024;2: 100046. https:\/\/doi.org\/10.1016\/j.glmedi.2023.100046.","journal-title":"J Med Surg Public Health"},{"key":"1708_CR46","doi-asserted-by":"publisher","first-page":"A12","DOI":"10.7326\/ACPJC-1995-123-3-A12","volume":"123","author":"WS Richardson","year":"1995","unstructured":"Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995;123:A12-13 (PMID: 7582737).","journal-title":"ACP J Club"},{"key":"1708_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis campbell systematic reviews. Campbell Syst Rev. 2022;18: e1230. https:\/\/doi.org\/10.1002\/cl2.1230.","journal-title":"Campbell Syst Rev"},{"key":"1708_CR48","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"1708_CR49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1076\/clin.12.1.43.1726","volume":"12","author":"RHB Benedict","year":"1998","unstructured":"Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins verbal learning test\u2014revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998;12:43\u201355. https:\/\/doi.org\/10.1076\/clin.12.1.43.1726.","journal-title":"Clin Neuropsychol"},{"key":"1708_CR50","unstructured":"Castellino SM, Donepezil in treating young patients with primary brain tumors previously treated with radiation therapy to the brain, NCT00452868, Updated August 8, 2018. https:\/\/clinicaltrials.gov\/study\/NCT00452868."},{"key":"1708_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"1708_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1708_CR53","unstructured":"R Core Team (2024). _R: a language and environment for statistical computing_. R Foundation for Statistical Computing, Vienna, Austria. <https:\/\/www.R-project.org\/>."},{"key":"1708_CR54","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org\/handbook."},{"key":"1708_CR55","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97\u2013111. https:\/\/doi.org\/10.1002\/jrsm.12.","journal-title":"Res Synth Methods"},{"key":"1708_CR56","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/EDE.0000000000001232","volume":"31","author":"L Lin","year":"2020","unstructured":"Lin L, Chu H. Meta-analysis of proportions using generalized linear mixed models. Epidemiology. 2020;31:713\u20137. https:\/\/doi.org\/10.1097\/EDE.0000000000001232.","journal-title":"Epidemiology"},{"key":"1708_CR57","doi-asserted-by":"publisher","DOI":"10.11613\/BM.2013.018","author":"ML McHugh","year":"2013","unstructured":"McHugh ML. The chi-square test of independence. Biochem Med. 2013. https:\/\/doi.org\/10.11613\/BM.2013.018.","journal-title":"Biochem Med"},{"key":"1708_CR58","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1136\/bmj.333.7568.597","volume":"333","author":"J Lau","year":"2006","unstructured":"Lau J, Ioannidis JPA, Terrin N, et al. The case of the misleading funnel plot. BMJ. 2006;333:597\u2013600. https:\/\/doi.org\/10.1136\/bmj.333.7568.597.","journal-title":"BMJ"},{"key":"1708_CR59","unstructured":"_ Efficacy and safety of donepezil hydrochloride in preadolescent and adolescent children with attention impairment following cancer treatment, NCT00688376, Updated December 14, 2021, https:\/\/clinicaltrials.gov\/study\/NCT00688376"},{"key":"1708_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-79948-3_1127","volume-title":"Encyclopedia of clinical neuropsychology","author":"S Belkonen","year":"2011","unstructured":"Belkonen S. Hopkins verbal learning test. In: Kreutzer JS, DeLuca J, Caplan B, editors. Encyclopedia of clinical neuropsychology. New York: Springer; 2011. https:\/\/doi.org\/10.1007\/978-0-387-79948-3_1127."},{"key":"1708_CR61","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1080\/23279095.2021.1887870","volume":"29","author":"Y Guo","year":"2022","unstructured":"Guo Y. A selective review of the ability for variants of the trail making test to assess cognitive impairment. Appl Neuropsychol Adult. 2022;29:1634\u201345. https:\/\/doi.org\/10.1080\/23279095.2021.1887870.","journal-title":"Appl Neuropsychol Adult"},{"key":"1708_CR62","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1080\/23279095.2021.1952590","volume":"30","author":"K Bauer","year":"2023","unstructured":"Bauer K, Malek-Ahmadi M. Meta-analysis of controlled oral word association test (COWAT) FAS performance in amnestic mild cognitive impairment and cognitively unimpaired older adults. Appl Neuropsychol Adult. 2023;30:424\u201330. https:\/\/doi.org\/10.1080\/23279095.2021.1952590.","journal-title":"Appl Neuropsychol Adult"},{"key":"1708_CR63","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000334525","volume":"32","author":"M Malek-Ahmadi","year":"2011","unstructured":"Malek-Ahmadi M, Small BJ, Raj A. The diagnostic value of controlled oral word association test-FAS and category fluency in single-domain amnestic mild cognitive impairment. Dement Geriatr Cogn Disord. 2011;32:235\u201340. https:\/\/doi.org\/10.1159\/000334525.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1708_CR64","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/26320843221089628","volume":"3","author":"CB Terwee","year":"2022","unstructured":"Terwee CB, Elsman EB, Roorda LD. Towards standardization of fatigue measurement: psychometric properties and reference values of the PROMIS Fatigue item bank in the dutch general population. Res Methods Med Health Sci. 2022;3:86\u201398. https:\/\/doi.org\/10.1177\/26320843221089628.","journal-title":"Res Methods Med Health Sci"},{"key":"1708_CR65","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jval.2018.03.013","volume":"21","author":"I Montan","year":"2018","unstructured":"Montan I, L\u00f6we B, Cella D, et al. General population norms for the functional assessment of chronic illness therapy (FACIT)-fatigue scale. Value Health. 2018;21:1313\u201321. https:\/\/doi.org\/10.1016\/j.jval.2018.03.013.","journal-title":"Value Health"},{"key":"1708_CR66","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13:63\u201374. https:\/\/doi.org\/10.1016\/S0885-3924(96)00274-6.","journal-title":"J Pain Symptom Manag"},{"key":"1708_CR67","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/NNR.0000000000000162","volume":"65","author":"S Ameringer","year":"2016","unstructured":"Ameringer S, Elswick RK, Menzies V, et al. Psychometric evaluation of the patient-reported outcomes measurement information system fatigue-short form across diverse populations. Nurs Res. 2016;65:279\u201389. https:\/\/doi.org\/10.1097\/NNR.0000000000000162.","journal-title":"Nurs Res"},{"key":"1708_CR68","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3389\/fnins.2019.00472","volume":"13","author":"D-D Li","year":"2019","unstructured":"Li D-D, Zhang Y-H, Zhang W, Zhao P. Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease. Front Neurosci. 2019;13:472. https:\/\/doi.org\/10.3389\/fnins.2019.00472.","journal-title":"Front Neurosci"},{"key":"1708_CR69","doi-asserted-by":"publisher","first-page":"101571","DOI":"10.1016\/j.eclinm.2022.101571","volume":"51","author":"T Baba","year":"2022","unstructured":"Baba T, Takeda A, Murakami A, et al. Effect of donepezil for dementia prevention in Parkinson\u2019s disease with severe hyposmia (The DASH-PD study): a randomized long-term placebo-controlled trial. eClinicalMedicine. 2022;51:101571. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101571.","journal-title":"eClinicalMedicine"},{"key":"1708_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2022.107134","volume":"213","author":"X Zhang","year":"2022","unstructured":"Zhang X, Lian S, Zhang Y, Zhao Q. Efficacy and safety of donepezil for mild cognitive impairment: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2022;213: 107134. https:\/\/doi.org\/10.1016\/j.clineuro.2022.107134.","journal-title":"Clin Neurol Neurosurg"},{"key":"1708_CR71","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3389\/fpsyt.2013.00105","volume":"4","author":"SL Risacher","year":"2013","unstructured":"Risacher SL, Wang Y, Wishart HA, et al. Cholinergic enhancement of brain activation in mild cognitive impairment during episodic memory encoding. Front Psychiatry. 2013;4:105. https:\/\/doi.org\/10.3389\/fpsyt.2013.00105.","journal-title":"Front Psychiatry"},{"key":"1708_CR72","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1200\/JCO.2004.05.128","volume":"22","author":"CA Meyers","year":"2004","unstructured":"Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004;22:157\u201365. https:\/\/doi.org\/10.1200\/JCO.2004.05.128.","journal-title":"J Clin Oncol"},{"key":"1708_CR73","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/00006123-200008000-00011","volume":"47","author":"O Tucha","year":"2000","unstructured":"Tucha O, Smely C, Preier M, Lange KW. Cognitive deficits before treatment among patients with brain tumors. Neurosurgery. 2000;47:324\u201334. https:\/\/doi.org\/10.1097\/00006123-200008000-00011.","journal-title":"Neurosurgery"},{"key":"1708_CR74","doi-asserted-by":"publisher","first-page":"E90","DOI":"10.1200\/EDBK_320813","volume":"41","author":"MW Parsons","year":"2021","unstructured":"Parsons MW, Dietrich J. Assessment and management of cognitive symptoms in patients with brain tumors. Am Soc Clin Oncol Educ Book. 2021;41:E90\u20139. https:\/\/doi.org\/10.1200\/EDBK_320813.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1708_CR75","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11910-012-0264-9","volume":"12","author":"JS Wefel","year":"2012","unstructured":"Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep. 2012;12:267\u201375. https:\/\/doi.org\/10.1007\/s11910-012-0264-9.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1708_CR76","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1212\/WNL.0000000000001861","volume":"85","author":"MJ Prust","year":"2015","unstructured":"Prust MJ, Jafari-Khouzani K, Kalpathy-Cramer J, et al. Standard chemoradiation for glioblastoma results in progressive brain volume loss. Neurology. 2015;85:683\u201391. https:\/\/doi.org\/10.1212\/WNL.0000000000001861.","journal-title":"Neurology"},{"key":"1708_CR77","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2017.2235","author":"A Zer","year":"2017","unstructured":"Zer A, Pond GR, Razak ARA, et al. Association of neurocognitive deficits with radiotherapy or chemoradiotherapy for patients with head and neck cancer. JAMA Otolaryngol Neck Surg. 2017. https:\/\/doi.org\/10.1001\/jamaoto.2017.2235.","journal-title":"JAMA Otolaryngol Neck Surg"},{"key":"1708_CR78","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.3390\/cancers13246191","volume":"13","author":"NS Voon","year":"2021","unstructured":"Voon NS, Abdul Manan H, Yahya N. Cognitive decline following radiotherapy of head and neck cancer: systematic review and meta-analysis of MRI correlates. Cancers. 2021;13:6191. https:\/\/doi.org\/10.3390\/cancers13246191.","journal-title":"Cancers"},{"key":"1708_CR79","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.neubiorev.2017.10.028","volume":"83","author":"LJ Bernstein","year":"2017","unstructured":"Bernstein LJ, McCreath GA, Komeylian Z, Rich JB. Cognitive impairment in breast cancer survivors treated with chemotherapy depends on control group type and cognitive domains assessed: a multilevel meta-analysis. Neurosci Biobehav Rev. 2017;83:417\u201328. https:\/\/doi.org\/10.1016\/j.neubiorev.2017.10.028.","journal-title":"Neurosci Biobehav Rev"},{"key":"1708_CR80","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1200\/JCO.2009.27.0827","volume":"28","author":"TA Ahles","year":"2010","unstructured":"Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28:4434\u201340. https:\/\/doi.org\/10.1200\/JCO.2009.27.0827.","journal-title":"J Clin Oncol"},{"key":"1708_CR81","doi-asserted-by":"publisher","DOI":"10.1097\/NNR.0000000000000660","author":"KR Oppegaard","year":"2023","unstructured":"Oppegaard KR, Mayo SJ, Armstrong TS, et al. An evaluation of the multifactorial model of cancer-related cognitive impairment. Nurs Res. 2023. https:\/\/doi.org\/10.1097\/NNR.0000000000000660.","journal-title":"Nurs Res"},{"key":"1708_CR82","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.30833","volume":"7","author":"SJ Mayo","year":"2024","unstructured":"Mayo SJ, Edelstein K, Atenafu EG, et al. Cognitive symptoms across diverse cancers. JAMA Netw Open. 2024;7: e2430833. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.30833.","journal-title":"JAMA Netw Open"},{"key":"1708_CR83","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11764-021-01023-9","volume":"16","author":"S Oerlemans","year":"2022","unstructured":"Oerlemans S, Schagen SB, Van Den Hurk CJ, et al. Self-perceived cognitive functioning and quality of life among cancer survivors: results from the PROFILES registry. J Cancer Surviv. 2022;16:303\u201313. https:\/\/doi.org\/10.1007\/s11764-021-01023-9.","journal-title":"J Cancer Surviv"},{"key":"1708_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.871","volume":"9","author":"C Pellegrini","year":"2021","unstructured":"Pellegrini C, D\u2019Antongiovanni V, Fornai M, et al. Donepezil improves vascular function in a mouse model of Alzheimer\u2019s disease. Pharmacol Res Perspect. 2021;9: e00871. https:\/\/doi.org\/10.1002\/prp2.871.","journal-title":"Pharmacol Res Perspect"},{"key":"1708_CR85","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.neuroscience.2015.01.058","volume":"290","author":"HB Guo","year":"2015","unstructured":"Guo HB, Cheng YF, Wu JG, et al. Donepezil improves learning and memory deficits in APP\/PS1 mice by inhibition of microglial activation. Neuroscience. 2015;290:530\u201342. https:\/\/doi.org\/10.1016\/j.neuroscience.2015.01.058.","journal-title":"Neuroscience"},{"key":"1708_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027632","volume":"6","author":"D Su","year":"2011","unstructured":"Su D, Zhao Y, Wang B, et al. Isoflurane-induced spatial memory impairment in mice is prevented by the acetylcholinesterase inhibitor donepezil. PLoS ONE. 2011;6: e27632. https:\/\/doi.org\/10.1371\/journal.pone.0027632.","journal-title":"PLoS ONE"},{"key":"1708_CR87","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00228-006-0168-1","volume":"62","author":"F Varsaldi","year":"2006","unstructured":"Varsaldi F, Miglio G, Scordo MG, et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer\u2019s disease patients. Eur J Clin Pharmacol. 2006;62:721\u20136. https:\/\/doi.org\/10.1007\/s00228-006-0168-1.","journal-title":"Eur J Clin Pharmacol"},{"key":"1708_CR88","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/FTD.0000000000000823","volume":"43","author":"Y Kagawa","year":"2021","unstructured":"Kagawa Y, Yamamoto Y, Ueno A, et al. Impact of CYP2D6, CYP3A5, and ABCB1 polymorphisms on plasma concentrations of donepezil and its metabolite in patients with Alzheimer disease. Ther Drug Monit. 2021;43:429\u201335. https:\/\/doi.org\/10.1097\/FTD.0000000000000823.","journal-title":"Ther Drug Monit"},{"key":"1708_CR89","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/PGPM.S211259","volume":"12","author":"T Yaowaluk","year":"2019","unstructured":"Yaowaluk T, Senanarong V, Limwongse C, et al. Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer\u2019s disease and vascular dementia. Pharmacogenom Pers Med. 2019;12:209\u201324. https:\/\/doi.org\/10.2147\/PGPM.S211259.","journal-title":"Pharmacogenom Pers Med"},{"key":"1708_CR90","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40265-022-01675-6","volume":"82","author":"P Glare","year":"2022","unstructured":"Glare P, Aubrey K, Gulati A, et al. Pharmacologic management of persistent pain in cancer survivors. Drugs. 2022;82:275\u201391. https:\/\/doi.org\/10.1007\/s40265-022-01675-6.","journal-title":"Drugs"},{"key":"1708_CR91","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/cncr.33981","volume":"128","author":"C Jiang","year":"2022","unstructured":"Jiang C, Deng L, Karr MA, et al. Chronic comorbid conditions among adult cancer survivors in the United States: results from the National Health Interview Survey, 2002\u20132018. Cancer. 2022;128:828\u201338. https:\/\/doi.org\/10.1002\/cncr.33981.","journal-title":"Cancer"},{"key":"1708_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231379","volume":"15","author":"ACS Palmer","year":"2020","unstructured":"Palmer ACS, Zortea M, Souza A, et al. Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: a randomized, double-blind, placebo-controlled trial. PLoS ONE. 2020;15: e0231379. https:\/\/doi.org\/10.1371\/journal.pone.0231379.","journal-title":"PLoS ONE"},{"key":"1708_CR93","doi-asserted-by":"publisher","first-page":"8172","DOI":"10.1002\/cam4.5619","volume":"12","author":"ZM Nakamura","year":"2023","unstructured":"Nakamura ZM, Deal AM, Park EM, et al. A phase II single-arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: feasibility, tolerability, acceptability, and preliminary effects. Cancer Med. 2023;12:8172\u201383. https:\/\/doi.org\/10.1002\/cam4.5619.","journal-title":"Cancer Med"},{"key":"1708_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084391","volume":"9","author":"S Gong","year":"2014","unstructured":"Gong S, Sheng P, Jin H, et al. Effect of methylphenidate in patients with cancer-related fatigue: a systematic review and meta-analysis. PLoS ONE. 2014;9: e84391. https:\/\/doi.org\/10.1371\/journal.pone.0084391.","journal-title":"PLoS ONE"},{"key":"1708_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/3942439","volume":"2020","author":"L Lv","year":"2020","unstructured":"Lv L, Mao S, Dong H, et al. Pathogenesis, assessments, and management of chemotherapy-related cognitive impairment (CRCI): an updated literature review. J Oncol. 2020;2020:1\u201311. https:\/\/doi.org\/10.1155\/2020\/3942439.","journal-title":"J Oncol"},{"key":"1708_CR96","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1080\/13854046.2020.1730444","volume":"35","author":"J Ryan","year":"2021","unstructured":"Ryan J, Woods RL, Murray AM, et al. Normative performance of older individuals on the Hopkins Verbal Learning Test-Revised (HVLT-R) according to ethno-racial group, gender, age and education level. Clin Neuropsychol. 2021;35:1174\u201390. https:\/\/doi.org\/10.1080\/13854046.2020.1730444.","journal-title":"Clin Neuropsychol"},{"key":"1708_CR97","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/cam4.5009","volume":"12","author":"J Huang","year":"2023","unstructured":"Huang J, Chan SC, Ngai CH, et al. Global incidence, mortality and temporal trends of cancer in children: a joinpoint regression analysis. Cancer Med. 2023;12:1903\u201311. https:\/\/doi.org\/10.1002\/cam4.5009.","journal-title":"Cancer Med"},{"key":"1708_CR98","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"key":"1708_CR99","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1158\/1055-9965.EPI-19-0941","volume":"29","author":"PJ Lupo","year":"2020","unstructured":"Lupo PJ, Spector LG. Cancer progress and priorities: childhood cancer. Cancer Epidemiol Biomarkers Prev. 2020;29:1081\u201394. https:\/\/doi.org\/10.1158\/1055-9965.EPI-19-0941.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1708_CR100","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1037\/a0016674","volume":"23","author":"L Ellenberg","year":"2009","unstructured":"Ellenberg L, Liu Q, Gioia G, et al. Neurocognitive status in long-term survivors of childhood CNS malignancies: a report from the childhood cancer survivor study. Neuropsychology. 2009;23:705\u201317. https:\/\/doi.org\/10.1037\/a0016674.","journal-title":"Neuropsychology"},{"key":"1708_CR101","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.3390\/curroncol30060422","volume":"30","author":"S Sharma","year":"2023","unstructured":"Sharma S, Brunet J. Young adults\u2019 lived experiences with cancer-related cognitive impairment: an exploratory qualitative study. Curr Oncol. 2023;30:5593\u2013614. https:\/\/doi.org\/10.3390\/curroncol30060422.","journal-title":"Curr Oncol"},{"key":"1708_CR102","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1186\/s12885-022-09806-8","volume":"22","author":"N Kerckhove","year":"2022","unstructured":"Kerckhove N, Tougeron D, Lepage C, et al. Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial. BMC Cancer. 2022;22:742. https:\/\/doi.org\/10.1186\/s12885-022-09806-8.","journal-title":"BMC Cancer"},{"key":"1708_CR103","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","volume":"155","author":"M Seretny","year":"2014","unstructured":"Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155:2461\u201370. https:\/\/doi.org\/10.1016\/j.pain.2014.09.020.","journal-title":"Pain"},{"key":"1708_CR104","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jphs.2019.05.009","volume":"140","author":"T Kawashiri","year":"2019","unstructured":"Kawashiri T, Shimizu S, Shigematsu N, et al. Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect. J Pharmacol Sci. 2019;140:291\u20134. https:\/\/doi.org\/10.1016\/j.jphs.2019.05.009.","journal-title":"J Pharmacol Sci"},{"key":"1708_CR105","doi-asserted-by":"publisher","first-page":"16418","DOI":"10.1523\/JNEUROSCI.1537-15.2015","volume":"35","author":"J Ferrier","year":"2015","unstructured":"Ferrier J, Bayet-Robert M, Dalmann R, et al. Cholinergic neurotransmission in the posterior insular cortex is altered in preclinical models of neuropathic pain: key role of muscarinic M2 receptors in donepezil-induced antinociception. J Neurosci. 2015;35:16418\u201330. https:\/\/doi.org\/10.1523\/JNEUROSCI.1537-15.2015.","journal-title":"J Neurosci"},{"key":"1708_CR106","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/jnci\/djab027","volume":"113","author":"AM Henneghan","year":"2021","unstructured":"Henneghan AM, Van Dyk K, Kaufmann T, et al. Measuring self-reported cancer-related cognitive impairment: recommendations from the cancer neuroscience initiative working group. JNCI J Natl Cancer Inst. 2021;113:1625\u201333. https:\/\/doi.org\/10.1093\/jnci\/djab027.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1708_CR107","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1002\/pon.4351","volume":"26","author":"C Yao","year":"2017","unstructured":"Yao C, Rich JB, Tirona K, Bernstein LJ. Intraindividual variability in reaction time before and after neoadjuvant chemotherapy in women diagnosed with breast cancer. Psychooncology. 2017;26:2261\u20138. https:\/\/doi.org\/10.1002\/pon.4351.","journal-title":"Psychooncology"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01708-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:45:48Z","timestamp":1764917148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01708-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":107,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1708"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01708-w","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No ethical approval and consent to participate were required as this study was based on previously published data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"196"}}